

## Special Issue

# Advances in Cell and Gene Therapy in Tumors: From Bench to Bedside

### Message from the Guest Editor

The goal of this Special Issue is to explore the potential of cell and gene therapy for the treatment of human tumors, aiming to bring together original research, reviews, perspectives, comments, and letters to editors that cover the latest advances and challenges in the development and application of cell and gene therapy in tumors. Potential subtopics include but are not limited to the following: the pre-clinical study of cell and gene therapy in tumors; the clinical application and management of cell and gene therapy in tumors; next-generation cell and gene therapy development; clinical trials of cell and gene therapy in human tumors; policies and guidelines of cell and gene therapy. **Keywords**

- cell therapy
- gene therapy
- genetically engineered cells
- cancer treatment
- clinical trials
- pre-clinical study

---

### Guest Editor

Dr. Shuhang Wang

Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, China

---

### Deadline for manuscript submissions

31 December 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/212040](https://mdpi.com/si/212040)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)